Last reviewed · How we verify
ICARIDIN
ICARIDIN is a marketed drug with a key composition patent expiring in 2028, positioning it as an established player in its therapeutic area. The drug's primary strength lies in its current market presence, leveraging its patent protection to maintain exclusivity and revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | ICARIDIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Repellents as Added Control Measure to Long Lasting Insecticidal Nets (NA)
- Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia (NA)
- Comparison Trial Between Two Repellent Products and a Positive Control Against Culicoides Nubeculosus Midges (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICARIDIN CI brief — competitive landscape report
- ICARIDIN updates RSS · CI watch RSS